Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,424 | 7,954 | 9,459 | 10,670 | 11,817 |
| Receivables | N/A | 24 | 24 | 24 | N/A |
| TOTAL | $6,829 | $8,286 | $9,914 | $11,022 | $12,154 |
| Non-Current Assets | |||||
| PPE Net | 235 | 245 | 246 | 262 | 231 |
| Other Non-Current Assets | 38 | 47 | 26 | 26 | 26 |
| TOTAL | $273 | $292 | $272 | $288 | $257 |
| Total Assets | $7,102 | $8,578 | $10,186 | $11,310 | $12,410 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 801 | 969 | 995 | 755 | 600 |
| Accrued Expenses | 170 | 182 | 175 | 164 | 164 |
| TOTAL | $971 | $2,586 | $2,583 | $919 | $764 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,458 | N/A | N/A | 1,390 | 1,367 |
| Other Non-Current Liabilities | 9,405 | 9,441 | 9,430 | 9,423 | 9,441 |
| TOTAL | $10,863 | $9,441 | $9,430 | $10,813 | $10,808 |
| Total Liabilities | $11,834 | $12,027 | $12,013 | $11,732 | $11,573 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3,245 | 3,245 | 3,245 | 3,245 | 3,245 |
| Common Shares | 325 | 325 | 325 | 325 | 325 |
| Retained earnings | -430,776 | -429,171 | -427,075 | -425,272 | -423,675 |
| Other shareholders' equity | -34 | -34 | -34 | -34 | -34 |
| TOTAL | $-4,733 | $-3,449 | $-1,826 | $-422 | $838 |
| Total Liabilities And Equity | $7,102 | $8,578 | $10,186 | $11,310 | $12,410 |